Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells Cambridge, UK: Horizon Discovery Group plc (LSE: HZD) (“Horizonâ€), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase (“GSâ€) […]
PISCATAWAY, N.J. — GenScript®, the world’s leading gene synthesis provider, today announced that it will provide research support to Harvard University scientist George Church, PhD, for his contributions to the Ultra-safe Cell project, the first grand scale community-wide initiative being undertaken by Genome Project-write and The Center for Excellence in Engineering Biology. The project aims […]
Pay Invoice
Latest Blogs
-
Federal R&D Obligations for the NIH Decline in FY24
March 27, 2025 3:02 pm
-
Paving The Way for Change: 10x Genomics Announces Corporate Strategies for a Fruitful 2025
February 26, 2025 1:05 pm
-
SLAS2025: Lab Automation and More
January 23, 2025 4:00 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
